## Shinya Shibutani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9187770/publications.pdf

Version: 2024-02-01

279798 302126 41 1,492 23 39 citations h-index g-index papers 41 41 41 724 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Translesional Synthesis on DNA Templates Containing a Single Abasic Site. Journal of Biological Chemistry, 1997, 272, 13916-13922.	3.4	157
2	Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 2000, 21, 1461-1467.	2.8	109
3	ldentification of Tamoxifenâ^'DNA Adducts Formed by α-Sulfate Tamoxifen and α-Acetoxytamoxifen. Chemical Research in Toxicology, 1997, 10, 189-196.	3.3	101
4	Tamoxifenâ^'DNA Adducts Detected in the Endometrium of Women Treated with Tamoxifen. Chemical Research in Toxicology, 1999, 12, 646-653.	3.3	88
5	Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis, 2000, 21, 1461-1467.	2.8	86
6	Translesional Synthesis Past Acetylaminofluorene-Derived DNA Adducts Catalyzed by Human DNA Polymerase κ and Escherichia coli DNA Polymerase IV. Biochemistry, 2001, 40, 15176-15183.	2.5	70
7	Miscoding Properties of 3,N4-Etheno-2â€~-deoxycytidine in Reactions Catalyzed by Mammalian DNA Polymerasesâ€. Biochemistry, 1996, 35, 14992-14998.	2.5	60
8	Quantitation of base substitutions and deletions induced by chemical mutagens during DNA synthesis in vitro. Chemical Research in Toxicology, 1993, 6, 625-629.	3.3	59
9	Genotoxic Mechanism of Tamoxifen in Developing Endometrial Cancer. Drug Metabolism Reviews, 2004, 36, 199-218.	3.6	55
10	Mutagenesis of theN-(Deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine DNA Adduct in Mammalian Cells. Journal of Biological Chemistry, 1999, 274, 27433-27438.	3.4	52
11	α-Hydroxylation of Tamoxifen and Toremifene by Human and Rat Cytochrome P450 3A Subfamily Enzymes. Chemical Research in Toxicology, 2003, 16, 1138-1144.	3.3	50
12	Influence of Flanking Sequence Context on the Mutagenicity of Acetylaminofluorene-Derived DNA Adducts in Mammalian Cellsâ€,‡. Biochemistry, 2001, 40, 3717-3722.	2.5	48
13	Mutagenic Events inEscherichia coliand Mammalian Cells Generated in Response to Acetylaminofluorene-Derived DNA Adducts Positioned in theNarl Restriction Enzyme Siteâ€. Biochemistry, 2002, 41, 14255-14262.	2.5	44
14	32P-Postlabeling/Polyacrylamide Gel Electrophoresis Analysis:Â Application to the Detection of DNA Adducts. Chemical Research in Toxicology, 2002, 15, 305-311.	3.3	42
15	Mutagenic Properties of Estrogen Quinone-Derived DNA Adducts in Simian Kidney Cells. Biochemistry, 2001, 40, 166-172.	2.5	41
16	Miscoding Potential of Tamoxifen-Derived DNA Adducts:  α-(N2-Deoxyguanosinyl)tamoxifen. Biochemistry, 1997, 36, 13010-13017.	2.5	40
17	Identification and Quantification of Tamoxifen-DNA Adducts in the Liver of Rats and Mice. Chemical Research in Toxicology, 2001, 14, 1006-1013.	3.3	39
18	Antiâ€breast cancer potential of SS5020, a novel benzopyran antiestrogen. International Journal of Cancer, 2011, 128, 974-982.	5.1	32

#	Article	IF	CITATIONS
19	Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Research, 2003, 63, 4402-6.	0.9	27
20	Identification of Tamoxifenâ $^{\circ}$ DNA Adducts Induced by α-Acetoxy-N-desmethyltamoxifen. Chemical Research in Toxicology, 2000, 13, 761-769.	3.3	26
21	Lifetime and Reactivity of an Ultimate Tamoxifen Carcinogen:  The Tamoxifen Carbocation. Journal of the American Chemical Society, 1998, 120, 13513-13514.	13.7	25
22	Translesion Synthesis Past Estrogen-Derived DNA Adducts by Human DNA Polymerases Î∙ and κâ€. Biochemistry, 2004, 43, 6304-6311.	2.5	25
23	Identification of hepatic tamoxifen–DNA adducts in mice: α-(N2-deoxyguanosinyl)tamoxifen and α-(N2-deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis, 2000, 21, 1737-1744.	2.8	24
24	Translesional Synthesis on DNA Templates Containing an Estrogen Quinone-Derived Adduct:  N2-(2-Hydroxyestron-6-yl)-2â€~-deoxyguanosine and N6-(2-Hydroxyestron-6-yl)-2â€~-deoxyadenosine. Biochemistry, 1998, 37, 13807-13815.	2.5	22
25	Mechanism of Frameshift (Deletion) Generated by Acetylaminofluorene-Derived DNA Adducts in Vitroâ€. Biochemistry, 2004, 43, 15929-15935.	2.5	20
26	Determination of Tamoxifenâ^'DNA Adducts in Leukocytes from Breast Cancer Patients Treated with Tamoxifen. Chemical Research in Toxicology, 2004, 17, 1577-1583.	3.3	19
27	Tamoxifenâ^'DNA Adducts Formed by α-AcetoxytamoxifenN-Oxideâ€. Chemical Research in Toxicology, 1999, 12, 1083-1089.	3.3	18
28	Site-specific adduct formation in oligomeric DNA using a new protecting group. Journal of the American Chemical Society, 1992, 114, 4923-4924.	13.7	17
29	32P-Postlabeling DNA Damage Assays. Methods in Molecular Biology, 2006, 314, 307-321.	0.9	15
30	Antiâ€breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions. International Journal of Cancer, 2010, 127, 1718-1726.	5.1	14
31	Preparation of Oligodeoxynucleotides Containing a Diastereoisomer of α-(N2-2â€~Deoxyguanosinyl)tamoxifen by Phosphoramidite Chemical Synthesis. Chemical Research in Toxicology, 2002, 15, 218-225.	3.3	13
32	Antiestrogens and the Formation of DNA Damage in Rats:  A Comparison. Chemical Research in Toxicology, 2006, 19, 852-858.	3.3	12
33	Miscoding Properties of $6\hat{l}^{\pm}$ - and $6\hat{l}^{2}$ -Diastereoisomers of the <i>N</i> <sup>2</sup> -(Estradiol-6-yl)- $2\hat{a}\in^{2}$ -deoxyguanosine DNA Adduct by Y-Family Human DNA Polymerases. Biochemistry, 2008, 47, 6695-6701.	2.5	10
34	Absence of DNA Adduct in the Leukocytes from Breast Cancer Patients Treated with Toremifene. Chemical Research in Toxicology, 2006, 19, 421-425.	3.3	9
35	Equine estrogen-induced mammary tumors in rats. Toxicology Letters, 2010, 193, 224-228.	0.8	8
36	Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate. International Journal of Cancer, 2008, 122, 2142-2147.	5.1	7

#	Article	IF	CITATIONS
37	Requirements for frameshift (deletion) during translesion synthesis. Environmental Mutagen Research, 2004, 26, 135-141.	0.1	3
38	Development of novel and safer anti-breast cancer agents, SS1020 and SS5020, based on a fundamental carcinogenic research. Genes and Environment, 2019, 41, 9.	2.1	2
39	Carcinogenic potential of fluorinated estrogens in mammary tumorigenesis. Toxicology Letters, 2020, 318, 99-103.	0.8	2
40	Tamoxifen-DNA adducts. , 2002, , .		1
41	Less Carcinogenic Chlorinated Estrogens Applicable to Hormone Replacement Therapy. International Journal of Molecular Sciences, 2021, 22, 7222.	4.1	0